Study Finds Ivermectin Reduces Covid-19 Mortality by 92%

A comprehensive medical study led by Brazilian endocrinologist Flávio A. Cadegiani, MD, MSc, Ph.D., which involves 88,012 patients, found that regular doses of ivermectin reduced mortality by 92% in patients with Covid-19.

The peer-reviewed study was published on Wednesday (August 31st) in the online medical journal Cureus. The study showed that people who used ivermectin as a preventive measure or had a history of taking the drug regularly before being infected with Covid-19 experienced significantly fewer deaths and hospitalizations due to Covid-19 infection. According to the study, those who took ivermectin regularly had a 92% lower risk of Covid-19 death compared to non-users and an 84% lower risk than irregular users.

The conventional dose referred to in the study was a course of ivermectin at a dose of 0.2mg/kg/day for two consecutive days, each 15 days apart, for a total of 150 days (i.e., 5 months). Therefore, the total dose of ivermectin for regular users was 180mg or more throughout the study program, and the total intake for non-regular users was up to 60mg.

Dr. Cadegiani is board certified endocrinologist with master’s and doctorate degrees in Clinical Endocrinology at the Federal University of São Paulo. He obtained his MD from the University of Brasilia in 2008, completed his residency in internal medicine at the same university in 2010, and was awarded a fellowship in Endocrinology and Metabolism at the Base Hospital of the Federal District (HBDF) in Brasilia, Brazil in 2012. Dr. Cadegiani’s highest achievements include earning a Ph.D. from the Federal University of São Paulo in just seven months, the shortest time in the university’s history, and winning gold medals in Mathematics, Chemistry, and Physics Brazilian Olympics at the same time when he was a teenager.